Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukine in MCI due to Alzheimer's Disease
NCT02667496Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Leukine with Placebo (2 arms). Primary endpoint: Change from baseline in standardized uptake value ratio as measured by PET using florbetapir F18 at 24 weeks. Planned start Nov 2016; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02667496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667496.